Risk assessment model for development of advanced age-related macular degeneration

Michael Klein, Peter J. Francis, Frederick L. Ferris, Sara C. Hamon, Traci E. Clemons

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Objective: To design a risk assessment model for development of advanced age-related macular degeneration (AMD) incorporating phenotypic, demographic, environmental, and genetic risk factors. Methods: Weevaluated longitudinal data from 2846 participants in the Age-Related Eye Disease Study. At baseline, these individuals had all levels of AMD, ranging from none to unilateral advanced AMD (neovascular or geographic atrophy). Follow-up averaged 9.3 years. We performed a Cox proportional hazards analysis with demographic, environmental, phenotypic, and genetic covariates and constructed a risk assessment model for development of advanced AMD. Performance of the model was evaluated using the C statistic and the Brier score and externally validated in participants in the Complications of Age-Related Macular Degeneration Prevention Trial. Results: The final model included the following independent variables: age, smoking history, family history of AMD (first-degree member), phenotype based on a modified Age-Related Eye Disease Study simple scale score, and genetic variants CFH Y402H and ARMS2 A69S. The model did well on performance measures, with very good discrimination (C statistic=0.872) and excellent calibration and overall performance (Brier score at 5 years=0.08). Successful external validation was performed, and a risk assessment tool was designed for use with or without the genetic component. Conclusions: We constructed a risk assessment model for development of advanced AMD. The model performed well on measures of discrimination, calibration, and overall performance and was successfully externally validated. This risk assessment tool is available for online use.

Original languageEnglish (US)
Pages (from-to)1543-1550
Number of pages8
JournalArchives of Ophthalmology
Volume129
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Macular Degeneration
Eye Diseases
Calibration
Geographic Atrophy
Demography
Smoking
History
Phenotype

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Risk assessment model for development of advanced age-related macular degeneration. / Klein, Michael; Francis, Peter J.; Ferris, Frederick L.; Hamon, Sara C.; Clemons, Traci E.

In: Archives of Ophthalmology, Vol. 129, No. 12, 12.2011, p. 1543-1550.

Research output: Contribution to journalArticle

Klein, Michael ; Francis, Peter J. ; Ferris, Frederick L. ; Hamon, Sara C. ; Clemons, Traci E. / Risk assessment model for development of advanced age-related macular degeneration. In: Archives of Ophthalmology. 2011 ; Vol. 129, No. 12. pp. 1543-1550.
@article{020c45cc1f32424ba2e492f3d5f6eb44,
title = "Risk assessment model for development of advanced age-related macular degeneration",
abstract = "Objective: To design a risk assessment model for development of advanced age-related macular degeneration (AMD) incorporating phenotypic, demographic, environmental, and genetic risk factors. Methods: Weevaluated longitudinal data from 2846 participants in the Age-Related Eye Disease Study. At baseline, these individuals had all levels of AMD, ranging from none to unilateral advanced AMD (neovascular or geographic atrophy). Follow-up averaged 9.3 years. We performed a Cox proportional hazards analysis with demographic, environmental, phenotypic, and genetic covariates and constructed a risk assessment model for development of advanced AMD. Performance of the model was evaluated using the C statistic and the Brier score and externally validated in participants in the Complications of Age-Related Macular Degeneration Prevention Trial. Results: The final model included the following independent variables: age, smoking history, family history of AMD (first-degree member), phenotype based on a modified Age-Related Eye Disease Study simple scale score, and genetic variants CFH Y402H and ARMS2 A69S. The model did well on performance measures, with very good discrimination (C statistic=0.872) and excellent calibration and overall performance (Brier score at 5 years=0.08). Successful external validation was performed, and a risk assessment tool was designed for use with or without the genetic component. Conclusions: We constructed a risk assessment model for development of advanced AMD. The model performed well on measures of discrimination, calibration, and overall performance and was successfully externally validated. This risk assessment tool is available for online use.",
author = "Michael Klein and Francis, {Peter J.} and Ferris, {Frederick L.} and Hamon, {Sara C.} and Clemons, {Traci E.}",
year = "2011",
month = "12",
doi = "10.1001/archophthalmol.2011.216",
language = "English (US)",
volume = "129",
pages = "1543--1550",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Risk assessment model for development of advanced age-related macular degeneration

AU - Klein, Michael

AU - Francis, Peter J.

AU - Ferris, Frederick L.

AU - Hamon, Sara C.

AU - Clemons, Traci E.

PY - 2011/12

Y1 - 2011/12

N2 - Objective: To design a risk assessment model for development of advanced age-related macular degeneration (AMD) incorporating phenotypic, demographic, environmental, and genetic risk factors. Methods: Weevaluated longitudinal data from 2846 participants in the Age-Related Eye Disease Study. At baseline, these individuals had all levels of AMD, ranging from none to unilateral advanced AMD (neovascular or geographic atrophy). Follow-up averaged 9.3 years. We performed a Cox proportional hazards analysis with demographic, environmental, phenotypic, and genetic covariates and constructed a risk assessment model for development of advanced AMD. Performance of the model was evaluated using the C statistic and the Brier score and externally validated in participants in the Complications of Age-Related Macular Degeneration Prevention Trial. Results: The final model included the following independent variables: age, smoking history, family history of AMD (first-degree member), phenotype based on a modified Age-Related Eye Disease Study simple scale score, and genetic variants CFH Y402H and ARMS2 A69S. The model did well on performance measures, with very good discrimination (C statistic=0.872) and excellent calibration and overall performance (Brier score at 5 years=0.08). Successful external validation was performed, and a risk assessment tool was designed for use with or without the genetic component. Conclusions: We constructed a risk assessment model for development of advanced AMD. The model performed well on measures of discrimination, calibration, and overall performance and was successfully externally validated. This risk assessment tool is available for online use.

AB - Objective: To design a risk assessment model for development of advanced age-related macular degeneration (AMD) incorporating phenotypic, demographic, environmental, and genetic risk factors. Methods: Weevaluated longitudinal data from 2846 participants in the Age-Related Eye Disease Study. At baseline, these individuals had all levels of AMD, ranging from none to unilateral advanced AMD (neovascular or geographic atrophy). Follow-up averaged 9.3 years. We performed a Cox proportional hazards analysis with demographic, environmental, phenotypic, and genetic covariates and constructed a risk assessment model for development of advanced AMD. Performance of the model was evaluated using the C statistic and the Brier score and externally validated in participants in the Complications of Age-Related Macular Degeneration Prevention Trial. Results: The final model included the following independent variables: age, smoking history, family history of AMD (first-degree member), phenotype based on a modified Age-Related Eye Disease Study simple scale score, and genetic variants CFH Y402H and ARMS2 A69S. The model did well on performance measures, with very good discrimination (C statistic=0.872) and excellent calibration and overall performance (Brier score at 5 years=0.08). Successful external validation was performed, and a risk assessment tool was designed for use with or without the genetic component. Conclusions: We constructed a risk assessment model for development of advanced AMD. The model performed well on measures of discrimination, calibration, and overall performance and was successfully externally validated. This risk assessment tool is available for online use.

UR - http://www.scopus.com/inward/record.url?scp=83455212184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455212184&partnerID=8YFLogxK

U2 - 10.1001/archophthalmol.2011.216

DO - 10.1001/archophthalmol.2011.216

M3 - Article

VL - 129

SP - 1543

EP - 1550

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 12

ER -